Fig. 3From: Efficacy and safety of erenumab in women with a history of menstrual migraineProportion of patients achieving ≥ 50% reduction from baseline in MMD. Data are shown as percentages. The gray shaded area represents months 4–6. *Statistically significantly different from placebo. Abbreviations: MMD, monthly migraine days; OR, odds ratioBack to article page